Game Of Thrones: Bayer Looks To Lead China’s OTC Market
This article was originally published in The Tan Sheet
The recent acquisition of Dihon Pharmaceutical Group marks progress toward Bayer’s goal of becoming the leader in the OTC sector in China. Dihon provides an entry into the TCM arena, which makes up about half of the OTC segment in China, the firm says.
You may also be interested in...
The breakup of the Hisun-Pfizer JV typifies an unhappy marriage between Chinese and MNC pharma firms in the generics segment in recent years, although the two companies will continue to work as commercial partners under a new framework. Scrip delves into the reasons for the split and also outlines why, China is, nevertheless, expected to see more joint ventures for innovative drugs.
Bayer acquired its second Chinese consumer health care firm to gain market share amid the country’s OTC consolidation trend. Dihon specializes in antifungal creams and herbal drugs for women’s and traditional Chinese medicines.
Multinational cold and cough OTC products have suffered a serious setback in China, as government restricts usage of drugs containing pseudoephedrine.